Eli Lilly and Company announced on October 13, 2025, that it will present new data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Annual Meeting, scheduled for October 17-21 in Berlin. A key highlight will be the primary overall survival analysis from the Phase 3 monarchE study of Verzenio in early breast cancer. The company will also present updated safety and efficacy data for several investigational therapies targeting various cancers, including ovarian, lung, bladder, and advanced breast cancer. This announcement precedes the company's Q3 2025 earnings report, which is expected on October 30, 2025. There is no specific market reaction analysis available for this announcement on October 14, 2025.